Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.38EUR
10:58am EST
Price Change (% chg)

€0.18 (+0.24%)
Prev Close
€76.20
Open
€75.99
Day's High
€76.59
Day's Low
€75.99
Volume
1,438,294
Avg. Vol
3,895,933
52-wk High
€89.95
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.61
Market Cap (Mil.): €101,115.50
Shares Outstanding (Mil.): 1,326.97
Dividend: 2.80
Yield (%): 3.67

Financials

  SASY.PA Industry Sector
P/E (TTM): 24.69 38.09 39.03
EPS (TTM): 3.09 -- --
ROI: -- 17.96 17.31
ROE: -- 18.76 18.22
Search Stocks

BRIEF-Zealand Pharma informs that Sanofi has confirmed development plans for LixiLan

* Zealand informs that Sanofi has confirmed development plans for LixiLan at Investor Relations Thematic Seminar

21 Nov 2014

UPDATE 4-Sanofi touts new drugs but diabetes outlook disappoints

* Sees up to six new drug launches in 2015, 18 by end 2020

20 Nov 2014

BRIEF-Sanofi chairman comments on drugmaker's outlook

PARIS, Nov 20 - Sanofi Chairman Serge Weinberg to reporters on a conference call on Thursday:

20 Nov 2014

Sanofi touts new drugs but diabetes outlook disappoints

PARIS - Sanofi, which sacked its chief executive three weeks ago, gave a weak sales outlook for its diabetes drugs on Thursday, overshadowing plans to reap more than 30 billion euros ($38 billion) from new medicines.

20 Nov 2014

Sanofi, Regeneron eczema drug gets FDA fast-track designation

PARIS, Nov 20 - Sanofi and its U.S. partner Regeneron said on Thursday the U.S. Food and Drug Administration had designated their dupilumab drug as "breakthrough therapy" in the treatment of atopic dermatitis, a chronic form of eczema, granting the product a fast-track development and review process.

20 Nov 2014

Without CEO, Sanofi touts new drugs in its pipeline

PARIS, Nov 20 - Sanofi set out its strategy for bringing several new drugs to the market on Thursday, in a bid to win over investors alarmed by the sudden ouster of its chief executive and problems in the field of diabetes.

20 Nov 2014

UPDATE 1-Sanofi draws up candidate shortlist for top job -source

* Fourtou to lead appointments and governance committee -source

18 Nov 2014

Sanofi draws up candidate shortlist for top job -source

PARIS, Nov 18 - Sanofi is drawing up a shortlist of candidates for the post of chief executive to replace Chris Viehbacher, ousted by the board last month, a source close to the French drugmaker told Reuters.

18 Nov 2014

Sanofi adds molecular biology expert Bonnie Bassler to board

PARIS, Nov 18 - Sanofi said on Tuesday it had nominated Bonnie Bassler, a molecular biology professor, as an independent member of its board of directors.

18 Nov 2014

Sanofi board to meet Tuesday - sources

PARIS, Nov 17 - Sanofi will hold a board meeting by telephone on Tuesday from 1100 GMT to 1200 GMT, according to two sources close to the French drugmaker.

17 Nov 2014

Earnings vs. Estimates

Search Stocks